Kather, Jakob Nikolas
Halama, Niels
Article History
Received: 20 November 2017
Revised: 20 February 2019
Accepted: 5 March 2019
First Online: 2 April 2019
Competing interests
: The authors declare that there is a conflict of interest. NH holds intellectual property on the use of CCR5 Inhibition in the Treatment of cancer and is a subject editor at the <i>British Journal of Cancer</i>.